The 25 references in paper E. Egorenkov A., V. Smirnov V., V. Kuzina N., S. Dementiev P., G. Ramenskaya V., Е. Егоренков А., В. Смирнов В., В. Кузина Н., С. Дементьев П., Г. Раменская В. (2018) “Методики фенотипирования изофермента CYP3A4, применяемые для персонализации фармакотерапии // CYP3A4 isoenzyme phenotyping for personalisation of pharmacotherapy” / spz:neicon:vedomostincesmp:y:2017:i:1:p:20-24

1
Denisov IG, Makris TM, Sligar SG, Schlichting I. Structure and chemistry of cytochrome P450. Chemical Reviews 2005; 105(6):
(check this in PDF content)
2
53–77. 2. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, Halpert JR. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001; 40(34): 10150–60.
(check this in PDF content)
3
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and Therapeutics 2013; 138(1): 103–41.
(check this in PDF content)
4
Ferguson CS, Tyndale RF. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in Pharmacological Sciences 2011; 32(12): 708–14.
(check this in PDF content)
5
Qui H, Mathas M, Nestler S, Bengel C, Nem D, Godtel-Armbrust U, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenetics and Genomics 2010; 20(3): 167–78.
(check this in PDF content)
6
Ratajewski M, Walczak-Drzewiecka A,Sa³kowskaA, Dastych J. Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor. Toxicological Letters 2011; 205(2): 146–53.
(check this in PDF content)
7
Ainslie GR, Wolf KK, Li Y, Wolf KK, Li Y, Connolly EA, Scarlett YV, Hull JH, Paine MF. Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates. The Journal of Pharmacology and Experimental Therapeutics 2014; 351(3): 576–84.
(check this in PDF content)
8
Kesel PM, Lambert WE, Stove CP. Alternative Sampling Strategies for Cytochrome P450 Phenotyping. Clin Pharmacokinet. 2016; 55(2): 169–84.
(check this in PDF content)
9
Elens L, Nieuweboer AJ, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, van Gelder T, Mathijssen RH, van Schaik RH. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics 2013; 23(3): 148–55.
(check this in PDF content)
10
KivistöKT, Kroemer HK. Use of Probe Drugs as Predictors of Drug Metabolism in Humans. The Journal of Clinical Pharmacology 1997; 37(1 Suppl): 40–8.
(check this in PDF content)
11
Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, et al. Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research 2000; 6(9): 3480–5.
(check this in PDF content)
12
Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics 2003; 73: 517–28.
(check this in PDF content)
13
Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the «Coopers-town5+1cocktail». Journal of Clinical Pharmacy and Therapeutics 2003; 74: 437–47.
(check this in PDF content)
14
Yin QQ, Lam SS, Lo CM, Chow MS. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Communications in Mass Spectrometry 2004; 18: 2921–33.
(check this in PDF content)
15
Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Journal of Clinical Pharmacy and Therapeutics 2006; 80: 257–63.
(check this in PDF content)
16
Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, et al. Development of the «Inje cocktail» for high-throughput evaluation of five human cytochrome P450 isoformsin vivo. Journal of Clinical Pharmacy and Therapeutics 2007; 82: 531–40.
(check this in PDF content)
17
Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. European Journal of Clinical Pharmacology 2003; 59(1): 23–8.
(check this in PDF content)
18
Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11(9): 781–91.
(check this in PDF content)
19
El Desoky ES, Mohamed HO, Farghaly WM, Hamed SA, Hedaya MA, Siest JP. Study of urinary 6 beta-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population. Pharmacological Research 2005; 51(6): 575–80.
(check this in PDF content)
20
Shibasaki H, Hosoda K, Goto M, Suzuki A, Yokokawa A, Ishii K, et al. Intraindividual and interindividual variabilities in endogenous cortisol 6b-hydroxylation clearance as an index forin vivoCYP3A phenotyping in humans. Drug Metab Dispos. 2013; 41(2): 475–9.
(check this in PDF content)
21
Shibasaki H, Kuroiwa M, Uchikura S, Tsuboyama S, Yokokawa A, Kume M, et al. Use of endogenous cortisol 6b-hydroxylation clearance for phenotypingin vivoCYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors. Steroids 2014; 87: 137–44.
(check this in PDF content)
22
Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EAC, et al. 4b-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. British Journal of clinical pharmacology 2015; 80(3): 560–8.
(check this in PDF content)
23
Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clinical Pharmacology and Therapeutics 2009; 86(2): 147–53.
(check this in PDF content)
24
Smirnov VV. Development of methods for determining cortisol and 6-b-hydroxycortisol in the urine in order to determine the activity of CYP3A4. Cand. Pharm. Sci [dissertation]. Moscow; 2011 (in Russian).
(check this in PDF content)
25
Smirnov VV, Savchenko AYu, Ramenskaya GV. Development and validation of methods of quantitative determination of endogenous cortisol and 6-b-hydroxycortisol in the urine in order to determine the activity of the isoenzyme CYP3A4. Biomeditsina 2010; 1(4): 56–60 (in Russian).
(check this in PDF content)